Physician profile
Scott D Groesch
NPI 1538107404
$2,532.85
in general payments reported to CMS, 2019-2025
22 companies · $194 in 2025
The $194 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,386 · 2020: $535 · 2021: $256 · 2024: $163 · 2025: $194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $356.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $387.54 | 2021-2025 | |
| Lilly USA, LLC | $311.89 | 2019-2025 | Zepbound, Mounjaro |
| Allergan, INC. | $272.20 | 2019-2020 | |
| Pfizer INC. | $231.07 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $205.95 | 2019-2020 | |
| Novo Nordisk INC | $191.52 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $171.12 | 2019-2020 | |
| Amgen INC. | $108.61 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $82.22 | 2019-2020 | |
| Amarin Pharma, INC. | $73.81 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $70.78 | 2019-2020 | |
| Astellas Pharma US INC | $68.41 | 2019 | |
| Novartis Pharmaceuticals Corporation | $64.67 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $56.70 | 2019-2020 | |
| Glaxosmithkline, LLC. | $47.43 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $41.07 | 2019-2020 | |
| Antares Pharma, INC. | $35.75 | 2020-2025 | Xyosted |
| Takeda Pharmaceuticals U.S.A., INC. | $33.90 | 2019 | |
| Phathom Pharmaceuticals, INC. | $23.58 | 2025 | Voquezna |
| Recor Medical INC | $22.93 | 2024 | Paradise Renal Denervation System |
| Shire North American Group INC | $18.43 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Groesch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.